Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
A clinical trial combines immunotherapy, common treatments, an antiretroviral drug, and SBRT for locally advanced pancreatic cancer.
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Dr. Andrea Califano is using systems biology and cell regulators to find new targets in the search for ways to stop pancreatic cancer cells.
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Pharmacist Trevor Christ emphasizes the importance of sharing your medication list with your medical team and pharmacist.
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.
Can losartan (a high blood pressure drug) and immunotherapy combined with standard chemotherapy and radiation be an effective combination against pancreatic cancer?
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?